Means for the diagnosis and therapy of CTCL

Details Means for the diagnosis and therapy of CTCL Means for the diagnosis and therapy of CTCL

2001-12-18

2008-07-15

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000

Reexamination Certificate

active

07399595

ABSTRACT:
A means for the diagnosis and therapy of T lymphomas, in particular Cutaneous T Cell Lymphomas (“CTCL”) are provided. Tumor markers which are universal for CTCL are described. More particularly, a molecule, termed SC5 by the inventors, an allelic form of p140, and biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL are described.

REFERENCES:
Alberts et al. (Molecular Biology of the Cell, 3rd edition, 1994, p. 465).
Lewin, B. (Genes VI. Oxford University Press, Inc., NY, Chapter 29, 1997).
Fu et al (EMBO Journal, 1996, vol. 15, pp. 4392-4401).
Mallampalli et al. (Biochem. J. vol. 318, 1996, pp. 333-341).
M. Nikolova, et al, “SC5, a novel functional cell structure expressed by Sezary syndrome cells,” J. Immunol, vol. 55, Supp. 1, 1995 (Abstract).
Daniela Pende, et al, “The Natural Killer Cell Receptor Specific for HLA-A Allotypes: A Novel Member of the p58/p70 Family of Inhibitory Receptors That Is Characterized by Three Immunoglobulin-like Domains and Is Expressed as a 140-kD Disulphide-linked Dimer,” J. Exp. Med., vol. 184, Aug. 1996, pp. 505-518.
Thomas Linnemann, et al, “Identification of Epitopes for CTCL-Specific Cytotoxic T Lymphocytes,” Advances in Experimental Medicine and Biology, Gene Therapy of Cancer, vol. 451, 1998, pp. 231-235.
Derwent Publications Ltd., XP 002167250 & RU 2104526, Feb. 10, 1998 (Abstract).
Martine Bagot, et al, “CD4 cutaneous T-cell lymphoma cells express the p140-killer cell immunoglogulin-like receptor,” Blood, vol. 97, No. 5, Mar. 1, 2001, pp. 1388-1391.
M. Nikolova, et al, “Identification of cell surface molecules characterizing human cutaneous cell lymphomas,” Leuk. Lymphoma, vol. 43, No. 4, Apr. 2002, Abstract.
Musette, P. et al. “Polymorphic expression of CD158k/p140/KIR3DL2 in Sézary patients”,Blood, Feb. 1, 2003, p. 1203, vol. 101, No. 3.
Carrington, M. et al.The KIR Gene Cluster, Available from the NCBI Bookshelf (http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=mono—003.TOC&depth=2), May 28, 2003, pp. pdf-1-pdf-48.

Affiliated with

Also associated with

Rating

Means for the diagnosis and therapy of CTCL does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Means for the diagnosis and therapy of CTCL, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means for the diagnosis and therapy of CTCL will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3971651